Dr. Devansu Tewari, MD
Gynecologic Oncology (Gynecologic Oncology Physician)
At a glance
- In the NPI registry since
- 2006
Licensed in California since 1999, according to the Medical Board of California. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Gynecologic Oncology Physician primary
CA license A068445 (first issued 1999; current) · CO license DR.0078460 (first issued 2026; active) · OR license MD26779 -
Obstetrics & Gynecology Physician
CO license DR.0078460 (first issued 2026; active)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Ibuprofen Other prescribers in Anaheim, CA | 24 |
| Tamoxifen Citrate Other prescribers in Anaheim, CA | 23 |
| Megestrol Acetate Other prescribers in Anaheim, CA | 20 |
| Ondansetron Hcl Other prescribers in Anaheim, CA | 20 |
| Lynparza (olaparib) | 18 |
| Nystatin Other prescribers in Anaheim, CA | 16 |
| Dexamethasone Other prescribers in Anaheim, CA | 13 |
| Everolimus | 11 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 3 companies reported 3 payments worth $212 in total to this clinician.
| AstraZeneca Pharmaceuticals LP | $122 |
|---|---|
| GlaxoSmithKline, LLC. | $63.75 |
| Intuitive Surgical, Inc. | $26.75 |
| Food and Beverage | $212 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 2 industry-funded studies in 2025, from 2 companies. The companies reported $70,473 in research payments for these studies, mostly to the institutions running them.
- Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer
AbbVie Inc. · Active, not recruiting · NCT05445778 - Trial to Assess the Safety and Preliminary Efficacy of GEN1055 on Malignant Solid Tumors as Monotherapy and as Combination Therapy
Genmab U.S., Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.